| 000 | 01643 a2200457 4500 | ||
|---|---|---|---|
| 005 | 20250513094904.0 | ||
| 264 | 0 | _c19960913 | |
| 008 | 199609s 0 0 eng d | ||
| 022 | _a0008-543X | ||
| 024 | 7 |
_a10.1002/(SICI)1097-0142(19960815)78:4<789::AID-CNCR15>3.0.CO;2-R _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aMiller, A A | |
| 245 | 0 | 0 |
_aFadrozole hydrochloride in postmenopausal patients with metastatic breast carcinoma. _h[electronic resource] |
| 260 |
_bCancer _cAug 1996 |
||
| 300 |
_a789-93 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntineoplastic Agents, Hormonal _xadverse effects |
| 650 | 0 | 4 | _aAromatase Inhibitors |
| 650 | 0 | 4 |
_aBreast Neoplasms _xblood |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 |
_aEstrogen Antagonists _xadverse effects |
| 650 | 0 | 4 |
_aFadrozole _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aNeoplasm Metastasis |
| 650 | 0 | 4 |
_aNeoplasms, Hormone-Dependent _xblood |
| 650 | 0 | 4 | _aPostmenopause |
| 650 | 0 | 4 | _aProspective Studies |
| 700 | 1 | _aLipton, A | |
| 700 | 1 | _aHenderson, I C | |
| 700 | 1 | _aNavari, R | |
| 700 | 1 | _aMulagha, M T | |
| 700 | 1 | _aCooper, J | |
| 773 | 0 |
_tCancer _gvol. 78 _gno. 4 _gp. 789-93 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1002/(SICI)1097-0142(19960815)78:4<789::AID-CNCR15>3.0.CO;2-R _zAvailable from publisher's website |
| 999 |
_c8753291 _d8753291 |
||